Clinical trials: Vinblastine
Kidney Neoplasms, Neoplasm Metastasis
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days.
- Trial name
- NCT00001570
- Testing
- PSC 833, vinblastine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma
- Trial name
- NCT00512980
- Testing
- prednisone, vinblastine, doxorubicin
- Where
- Germany
- Sponsor
- University of Cologne
Melanoma (Skin)
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00003027
- Testing
- aldesleukin, filgrastim, recombinant interferon alfa
- Where
- 94 sites in United States
- Volunteers
- 482 people
- Sponsor
- Eastern Cooperative Oncology Group
Recurrent Lymphoma, Refractory Lymphoma
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
- Conditions
- Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours, Central Nervous System
- Trial name
- NCT02343718
- Testing
- Vinblastine, Temsirolimus
- Where
- 6 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer, Kidney Neoplasm
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
The clinical study entitled "A Phase I Study of Infusional Chemotherapy with the P-glycoprotein Antagonist PSC 833" seeks to determine the maximum tolerated dose for a proposed P-glycoprotein antagonist, PSC 833.
- Conditions
- Breast Cancer, Kidney Neoplasm, Lymphoma, Neoplasm Metastasis
- Trial name
- NCT00001302
- Testing
- PSC 833
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as vinblastine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352495
- Testing
- carboplatin, vinblastine sulfate
- Where
- 21 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Hodgkin Disease
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD chemotherapy.
- Trial name
- NCT00038558
- Testing
- Filgrastim SD/01, Adriamycin, Bleomycin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Low Grade Glioma
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less…
- Trial name
- NCT02840409
- Testing
- Vinblastine, Bevacizumab
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 109 people
- Sponsor
- The Hospital for Sick Children
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Hodgkin Lymphoma, Adult
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
- Trial name
- NCT06984146
- Testing
- Nivolumab, Doxorubicin, Vinblastine
- Where
- Russia
- Volunteers
- 54 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Hodgkin's Disease
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
120 subjects with Hodgkin's disease will be randomly divided into two groups: Group I receiving R-mabHD and Group II receiving a combination of Adriamycin,Bleomycin,Vinblastine and Dacarbazine.
- Trial name
- NCT00797472
- Testing
- R-mabHD, ABVD
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- American Scitech International
Melanoma, Skin Cancer
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00002882
- Testing
- Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
This phase II trial will study the effectiveness and toxicity of sequential high dose MVAC followed by gemcitabine and cisplatin, as first line treatment in patients with locally advanced or metastatic bladder cancer.
- Trial name
- NCT00635726
- Testing
- Methotrexate, Vinblastine, Doxorubicin
- Where
- 7 sites in Greece
- Volunteers
- 41 people
- Sponsor
- Hellenic Oncology Research Group
Sarcoma
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
RATIONALE: Drugs used in chemotherapy, such as vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061893
- Testing
- celecoxib, cyclophosphamide, doxorubicin hydrochloride
- Where
- 101 sites in United States, Australia and 2 more
- Volunteers
- 38 people
- Sponsor
- Children's Oncology Group
Desmoid Tumor
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003019
- Testing
- methotrexate, vinblastine sulfate
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 28 people
- Sponsor
- Children's Oncology Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014274
- Testing
- carboplatin, gemcitabine hydrochloride, methotrexate
- Where
- 29 sites in Austria, Belgium and 9 more
- Volunteers
- 238 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hodgkin Lymphoma
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
- Trial name
- AVD-Rev (NCT01056679)
- Testing
- Doxorubicine, DTIC, Lenalidomide
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Cologne
Stage IV Melanoma
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other…
- Trial name
- NCT00498979
- Testing
- recombinant interferon alfa-2b, cisplatin, sodium stibogluconate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Melanoma
Metronomic Therapy in Patients With Metastatic Melanoma
SUMMARY: Metronomic Therapy in Patients with Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine. Patients with measurable metastatic melanoma are eligible.
- Trial name
- NCT01542255
- Testing
- vinblastine, Cyclophosphamide, dacarbazine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Classical Hodgkin Lymphoma
Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
This study evaluates bendamustine in patients aged over 60 years with classical Hodgkin Lymphoma treated by prednisone, vinblastine and doxorubicin. 90 patients will be enrolled in this study.
- Trial name
- PVAB (NCT02414568)
- Testing
- Bendamustine, Prednisone, Vinblastine
- Where
- 40 sites in Belgium, France
- Volunteers
- 90 people
- Sponsor
- The Lymphoma Academic Research Organisation